✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchCBDTHCAging Why This Matters Clinicians managing patients with fatty liver disease now have preliminary evidence...
Daily Digest: Last 6 Hours: Cognitive Safety, Liver Disease Breakthroughs, and the Drug Testing Problem That Won’t Go Away — March 06, 2026
A synthesis of 20 recently added cannabis articles — key themes, clinical context, and Dr. Caplan’s take.
Daily Digest: Last 48 Hours: Cognitive Safety, End-of-Life Access, and the Impairment Testing Problem — March 06, 2026
A synthesis of 102 recently added cannabis articles — key themes, clinical context, and Dr. Caplan’s take.
Natural Approaches to Managing Chronic Inflammation – WorldHealth.net
WHY IT MATTERS: Patients managing chronic inflammatory conditions now have growing scientific rationale to discuss cannabinoid-based options with their physicians, but translating that science into safe, effective protocols still requires careful medical guidance rather than self-directed supplementation. CLINICAL OVERVIEW: The endocannabinoid system is a legitimate and increasingly well-characterized biological network that helps regulate immune tone and inflammatory signaling through receptors distributed throughout immune tissues, the gut, and the central nervous system. Phytocannabinoids such as CBD and THC interact with this system in ways that can modulate cytokine production, microglial activation, and oxidative stress pathways relevant to chronic inflammatory conditions.
Natural Neuroprotection: Exploring the Potential of Non-Psychoactive Cannabinoids
WHY IT MATTERS: Patients and caregivers exploring cannabinoid options for neurological conditions should understand that while the basic science is genuinely promising, the gap between preclinical findings and proven clinical treatments means these approaches are best pursued under informed medical guidance rather than based on headlines alone. CLINICAL OVERVIEW: The endocannabinoid system plays a fundamental role in regulating neuronal health, modulating inflammation, oxidative stress, and cell survival pathways that are central to neurodegenerative disease processes. Non-psychoactive cannabinoids such as CBD, CBG, and CBDV interact with receptors and signaling cascades throughout the central nervous system in ways that may slow or interrupt the progression of conditions like Alzheimer’s disease, Parkinson’s disease, and traumatic brain injury sequelae.
Cannabis compounds show promise in fighting fatty liver disease, scientists say – AZERTAC
WHY IT MATTERS: Patients with fatty liver disease or metabolic syndrome may eventually have access to cannabinoid-based therapies as an adjunct treatment option, but only after human clinical trials confirm the safety and efficacy signals seen in early research. CLINICAL OVERVIEW: Emerging preclinical research is examining how non-psychoactive cannabinoids, particularly CBD and CBG, may influence hepatic lipid metabolism and reduce fat accumulation in liver tissue. These compounds appear to interact with endocannabinoid receptors and metabolic pathways involved in fatty acid synthesis and inflammation, offering a potential therapeutic avenue for metabolic-associated steatotic liver disease.
Study Finds No Link Between Lifetime Cannabis Use and Cognitive Decline in Older Adults
✦ New CED Clinical Relevance #78 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. NeurologyResearchAgingSafety Why This Matters Clinicians counseling older adult patients about cannabis use can now reference...
Daily Digest: Last 24 Hours: Cognitive Safety in Older Adults, End-of-Life Access, and the Regulatory Gaps That Still Hurt Patients — March 06, 2026
A synthesis of 68 recently added cannabis articles — key themes, clinical context, and Dr. Caplan’s take.
Daily Digest: Last 9 Hours: Cognitive Safety Data, End-of-Life Access, and Regulatory Friction — March 05, 2026
A synthesis of 68 recently added cannabis articles — key themes, clinical context, and Dr. Caplan’s take.
Study Shows Lifetime Cannabis Use Not Associated with Cognitive Decline or Dementia …
✦ New CED Clinical Relevance #78 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. ResearchNeurologyAgingSafety Why This Matters Clinicians can use this evidence to reassure older patients that lifetime...